Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million

Reuters2026/08/06 20:08

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Celldex posted a Q2 net loss of $73.5 million, or ($0.94) per share, widening from a $56.6 million loss a year earlier.
R&D expense climbed 24.54% to $67.5 million on higher barzolvolimab trial and contract manufacturing costs and higher headcount.
G&A expense rose 25.96% to $13.1 million, driven by higher barzolvolimab commercial planning costs; revenue was no material revenue.
Cash, cash equivalents and marketable securities totaled $717.6 million at June 30, up from $451.5 million at March 31 on a $323.8 million offering.
Phase 3 barzolvolimab CSU topline data expected Sept/Oct 2026 with a BLA planned for 2027; Celldex expects cash to fund operations through 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005316), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million

You may also like

Crypto prices